Survey of Health Preferences in Cancer Patients: a Study Protocol for a Prospective, Longitudinal Cohort Using Online Survey
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 198
- 试验地点
- 1
- 主要终点
- Health utilities for SF-6Dv2 before chemotherapy
研究概览
简要总结
This study will evaluate health utilities in patients with breast or colorectal cancer.
详细描述
The cost-utility analysis (CUA) is an increasingly used method to help health decision-maker. The CUA uses the Quality Adjusted Life Years (QALY) that combines the length of life with the health related quality of life (HRQoL) into a single score.
In Quebec, no QALY calculation tool has been adapted to its linguistic and socio-cultural context, neither for its general population nor for a particular subpopulation, like patients with cancer.
The objectives will be to analyze the extent of the divergence in terms of health states utilities between the general population and patients with breast or colorectal cancer; to develop a QALY preference weights dataset for patients with cancer; to perform "mapping" with different health-related quality of life questionnaires by correlating SF6Dv2 with EQ-5D-5L, EORTC QLQ-C30 and FACT- G. The data will be collected with a self-administered online survey. Patients outcomes will be measured at the beginning of the chemotherapy treatment cycle and about 8 days after the start of chemotherapy. Health utilities will be measured with a hybrid method using the time-trade-off (TTO) and the discrete experimental choice (DCE) method using SF6Dv2 questionnaire for health states.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •to be 18 years of age or older;
- •to reside in Quebec;
- •have already had a chemotherapy treatment cycle;
- •be on the eve of a new round of chemotherapy treatment;
- •have breast or colorectal cancer
排除标准
- •being over 80 years of age;
- •not be able to complete a computer questionnaire;
- •can not read or write in French;
- •not be able to sign a consent form;
- •the only treatment offered is surgery;
- •presence of metastases to the brain;
- •patient with delirium, psychosis or severe depression (i.e. chronic condition with treatment)
结局指标
主要结局
Health utilities for SF-6Dv2 before chemotherapy
时间窗: Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days)
Health utilities measured by SF-6Dv2 health states using a hybrid method combining time-trade-off (TTO) and discrete choice experiment (DCE)
Health utilities for SF-6Dv2 after the start of the chemotherapy
时间窗: 8 days after the start of the chemotherapy
Health utilities measured by SF-6Dv2 health states using a hybrid method combining time-trade-off (TTO) and discrete choice experiment (DCE)
次要结局
- Health utilities with the EuroQol five-dimensional questionnaire with five response levels (EQ-5D-5L) before chemotherapy(Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days))
- Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy(8 days after the start of the chemotherapy)
- Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires before chemotherapy(Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days))
- Health related quality of life (HRQoL) scores from EORTC QLQ-C30 questionnaire before chemotherapy before chemotherapy(Within two days before the start of a chemotherapy treatment cycle (standard treatment; each cycle is 21 days))
- Health utilities with the EuroQol five-dimensional questionnaire with five response levels (EQ-5D-5L) after chemotherapy(8 days after the start of the chemotherapy)
- Health related quality of life (HRQoL) scores from EORTC QLQ-C30 questionnaire before after chemotherapy(8 days after the start of the chemotherapy)
研究者
Thomas G. Poder
Principal Investigator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke